MULTIPLE MYELOMA

During a Targeted Oncology™ Case-Based Roundtable™ event, Shaji Kumar, MD, discussed with participants the key considerations of administering the bispecific T-cell engager teclistamab for patients with relapsed/refractory multiple myeloma.

In a live virtual event, Jens Hillengass discussed the results of the MajesTEC-1 study and how teclistamab is used to treat patients with relapsed/refractory multiple myeloma. This is the second article in a 2-article series on this case.

Natalie Callander, MD, offers advice for community oncologists and discusses unmet needs in treating transplant-preferred patients with newly diagnosed MM.

An overview of recent data from the SKylaRK and GMMG-HD7 trials evaluating non-daratumumab-based regimens for patients with transplant-preferred NDMM.

Natalie Callander, MD, details findings from her study, evaluating the impact of quadruplet therapy on newly diagnosed patients with high-risk multiple myeloma.

Insights on how the subgroup analysis of the MASTER trial informs the role of autologous stem cell transplantation and the use of quadruplet therapy for elderly patients.

Natalie Callander, MD, reviews the results and quality-of-life outcomes from the GRIFFIN trial on Dara-RVd for patients with transplant-eligible NDMM.

An expert oncologist discusses the role of stem cell transplantation and currently available therapies for the treatment of newly diagnosed multiple myeloma.

Natalie Callander, MD, presents the case of a 61-year-old woman with transplant-preferred newly diagnosed multiple myeloma (NDMM) and offers her initial impressions.

In an interview with Targeted Oncology, Prerna Mewawalla discussed the role of bispecific antibodies in multiple myeloma treatment and options to consider before patients reach the relapsed/refractory setting.

Emma Searle, PhD, discusses the dosing approach of the MajestTEC-2 trial (NCT04722146) and sequencing teclistamab (Tecvayli) in patients with multiple myeloma.

Emma Searle, discusses safety results of the MajestTEC-2 trial which combined teclistamab with daratumumab and lenalidomide in patients with multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discussed the treatment paradigm for relapsed/refractory multiple myeloma and how the BCMA target now plays a role.

In a live virtual event, Jens Hillengass discussed the available treatment strategies for patients with relapsed/refractory multiple myeloma. This is first of 2 articles based on this event.

Positive data from the phase 3 KarMMA-3 study has led to multiple regulatory applications being accepted for ide-cel as a treatment option for patients with relapsed/refractory multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Douglas W. Sborov, MD, MS, discussed possible therapy options for a patient who relapsed after receiving bortezomib, lenalidomide, and dexamethasone followed by autologous stem cell transplant.

The FDA has now granted OM-301 2 orphan drug designations for the treatment of patients with multiple myeloma and acute myeloid leukemia.

In an interview with Targeted Oncology, Ajay Nooka, MD, discussed findings from the phase 3 KarMMa-3 trial and the use of ide-cel for the treatment of patients with relapsed/refractory multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Surbhi Sidana, MD, discussed with participants their thoughts on the future of transplantation in multiple myeloma. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Mohammadbagher Ziari, MD, discussed with participants how they approach later lines of therapy for patients with multiple myeloma.

Rebecca Silbermann, MD, MMS, discusses the relevance of patient-reported outcomes from the phase 2 GRIFFIN study and the importance of individualizing treatment for patients with multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, discussed considerations when using selinexor with various drug combinations in later-line multiple myeloma therapy. This is the second of 2 articles based on this event.

CB-011 has received a fast track designation from the FDA for the treatment of relapsed/refractory multiple myeloma and is being investigated in the ongoing CaMMouflage study.

During a Targeted Oncology™ Case-Based Roundtable™ event, Suzanne Lentzsch, MD, PhD, discussed with participants their views on the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Surbhi Sidana, MD, discussed with participants how they use quadruplet or triplet frontline regimens for patients with transplant-eligible multiple myeloma. This is the first of 2 articles based on this event.